Reference number : GC-2017-Q3-00650, amendment number : , agreement type : G, recipient legal name : Accili, Eric (The University of British Columbia), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Plus Grants for universities, program name french : Subvention d'engagement partenarial Plus pour les universités, program purpose english : Salmonella infections represent a significant public health concern and disease burden. Significant sources of_x000D_
infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of_x000D_
Salmonella infections in poultry products is one means to reduce human infections. While advances have been_x000D_
made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure_x000D_
on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities._x000D_
NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that_x000D_
could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest_x000D_
poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are_x000D_
being tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on the_x000D_
expertise of Dr. Eric Accili in the fields of protein biochemistry and gastrointestinal (GI) tract biology. This_x000D_
project proposes to develop antibody formulations appropriate for application in the GI tract. The development_x000D_
of a Salmonella-selective antibody that is highly effective in the GI tract would benefit Canadian and World_x000D_
populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generated_x000D_
by NovoBind in delivering this product would also be an economic boost to Canada., program purpose french : Salmonella infections represent a significant public health concern and disease burden. Significant sources of_x000D_
infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of_x000D_
Salmonella infections in poultry products is one means to reduce human infections. While advances have been_x000D_
made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure_x000D_
on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities._x000D_
NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy that_x000D_
could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvest_x000D_
poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are_x000D_
being tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on the_x000D_
expertise of Dr. Eric Accili in the fields of protein biochemistry and gastrointestinal (GI) tract biology. This_x000D_
project proposes to develop antibody formulations appropriate for application in the GI tract. The development_x000D_
of a Salmonella-selective antibody that is highly effective in the GI tract would benefit Canadian and World_x000D_
populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generated_x000D_
by NovoBind in delivering this product would also be an economic boost to Canada., agreement title english : Antibody formulation for the gastrointestinal tract, agreement title french : Antibody formulation for the gastrointestinal tract, agreement number : EGP2, agreement value : 12500.0, agreement start date : 2017-12-13, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada